Free Trial

Asset Management One Co. Ltd. Cuts Stock Holdings in DaVita Inc. $DVA

DaVita logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Asset Management One Co. Ltd. cut its stake in DaVita by 92.8% in Q4, selling 16,563 shares and leaving it with 1,280 shares worth about $145,000.
  • Other institutions were net buyers — notably Goldman Sachs raised its holding to 179,140 shares (~$27.4M) — and institutional investors now own 90.12% of the company.
  • DaVita beat Q4 estimates with EPS of $3.40 (vs. $3.24 est.) and revenue up 9.9%, set FY2026 guidance of 13.60–15.00 EPS, while analysts' consensus remains a "Hold" with an average price target of $155.80.
  • MarketBeat previews the top five stocks to own by May 1st.

Asset Management One Co. Ltd. lowered its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 92.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,280 shares of the company's stock after selling 16,563 shares during the quarter. Asset Management One Co. Ltd.'s holdings in DaVita were worth $145,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of the business. NewEdge Advisors LLC boosted its stake in shares of DaVita by 20.8% during the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company's stock worth $78,000 after purchasing an additional 88 shares during the period. Goldman Sachs Group Inc. lifted its holdings in DaVita by 19.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company's stock valued at $27,403,000 after buying an additional 28,739 shares in the last quarter. Cerity Partners LLC lifted its holdings in DaVita by 7.0% during the 2nd quarter. Cerity Partners LLC now owns 2,638 shares of the company's stock valued at $376,000 after buying an additional 172 shares in the last quarter. Bank of Nova Scotia lifted its holdings in DaVita by 3.8% during the 2nd quarter. Bank of Nova Scotia now owns 4,813 shares of the company's stock valued at $686,000 after buying an additional 176 shares in the last quarter. Finally, Natixis lifted its holdings in DaVita by 80.9% during the 2nd quarter. Natixis now owns 7,297 shares of the company's stock valued at $1,039,000 after buying an additional 3,264 shares in the last quarter. Institutional investors own 90.12% of the company's stock.

DaVita Stock Performance

Shares of DVA stock opened at $151.80 on Friday. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $159.42. The firm has a market capitalization of $10.14 billion, a price-to-earnings ratio of 15.32, a PEG ratio of 0.54 and a beta of 0.92. The stock's 50-day simple moving average is $150.92 and its 200-day simple moving average is $130.74.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.24 by $0.16. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The business had revenue of $3.62 billion for the quarter, compared to analyst estimates of $3.51 billion. During the same quarter in the prior year, the business posted $2.24 EPS. DaVita's revenue for the quarter was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, equities analysts forecast that DaVita Inc. will post 14.16 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on DVA. Truist Financial set a $158.00 price objective on shares of DaVita in a report on Thursday, February 5th. UBS Group lifted their price objective on shares of DaVita from $186.00 to $190.00 and gave the company a "buy" rating in a report on Wednesday, February 4th. Barclays lifted their price objective on shares of DaVita from $143.00 to $158.00 and gave the company an "equal weight" rating in a report on Tuesday, February 3rd. Zacks Research lowered shares of DaVita from a "strong-buy" rating to a "hold" rating in a report on Monday, April 6th. Finally, Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Saturday, February 21st. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $155.80.

View Our Latest Analysis on DVA

About DaVita

(Free Report)

DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

Featured Articles

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

Institutional Ownership by Quarter for DaVita (NYSE:DVA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in DaVita Right Now?

Before you consider DaVita, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.

While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines